RegWardenFDA facility compliance records
Recall

Class II — Dale Medical Products, Inc.

Recalling firmDALE MEDICAL PRODUCTS, INC.
Registered facilityDALE MEDICAL PRODUCTS, INC. (the firm's only registered facility)
ClassificationClass II
StatusTerminated
ReasonET Tube Holders contain an adhesive faceplate that may lose its adhesive properties and will not adhere to the patient's face.
ProductDale Medical Stabilock Endotracheal Adhesive Base Product # 273 The Dale Stabilock Endotracheal Tube Bolder 270 is a 2 piece device consisting of an adhesive base, Dale product number 273, that attaches to the patient's skin and a cushioned neckband with tube channel that attaches with hook & loop closures. The 270 is used to secure and stabilize endotracheal tubes, preventing unnecessary movement which can help prevent accidental .extubation
Quantity34,770 total
DistributionWorldwide Distribution -US ( Nationwide) and Internationally to Canada, Costa Rica, Norway, Paraguay, Ireland, Panama, Ecuador, Hong Kong, Malaysia, Italy, UAE, Guatemala, Iceland, Indonesia, and Saudi Arabia.
Initiated2017-03-24
Classified2017-05-03
Terminated2018-05-21
Recall numberZ-1928-2017
InitiationVoluntary: Firm initiated

Source: U.S. FDA via openFDA (opens in a new tab) (device registration & enforcement). Data as of 2026-10-06. Verify this recall record at FDA → (opens in a new tab)

Cite this record

RegWarden. “Class II recall — Dale Medical Products, Inc. (Z-1928-2017).” Compiled from U.S. FDA public records (openFDA; FDA Data Dashboard). Data as of 2026-10-06. https://regwarden.com/recall/76965/

Not open yet

Alerts for DALE MEDICAL PRODUCTS, INC.

Watchlist alerts will email you when FDA publishes a new recall, inspection classification, or warning letter for a facility you follow. They aren't open to the public yet — leave your email and we'll tell you when they are.

Planned

Want a one-page facility brief?

A single-page summary of this facility's registration and recall history for diligence. Not selling it yet — register interest and we'll follow up.